Abstract
Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia) and zoledronic acid (Zometa), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Apoptosis
-
Bone Density Conservation Agents / adverse effects*
-
Bone Density Conservation Agents / pharmacokinetics
-
Bone Remodeling / drug effects
-
Contraindications
-
Diphosphonates / adverse effects*
-
Diphosphonates / pharmacokinetics
-
Humans
-
Jaw / blood supply
-
Jaw / metabolism
-
Jaw Diseases / chemically induced*
-
Jaw Diseases / metabolism
-
Jaw Diseases / prevention & control
-
Neovascularization, Physiologic / drug effects
-
Oral Hygiene
-
Oral Surgical Procedures
-
Osteoclasts / drug effects
-
Osteonecrosis / chemically induced*
-
Osteonecrosis / metabolism
-
Osteonecrosis / prevention & control
-
RANK Ligand / antagonists & inhibitors
Substances
-
Bone Density Conservation Agents
-
Diphosphonates
-
RANK Ligand